REVOLADE 50 MG
ELTROMBOPAG (ELTROMBOPAG OLAMINE) : 50 MG · DIN 02361833 · NOVARTIS PHARMACEUTICALS CANADA INC
Health Canada status: MARKETED
What is REVOLADE?
REVOLADE 50 MG contains ELTROMBOPAG (ELTROMBOPAG OLAMINE) : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 02361833, held by NOVARTIS PHARMACEUTICALS CANADA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 16-Feb-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is REVOLADE used for?
Chronic immune thrombocytopenia (ITP) in adults and pediatrics ≥1 year; thrombocytopenia in chronic hepatitis C (HCV) for interferon therapy; adult severe aplastic anemia (SAA).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02361833 |
|---|---|
| Brand name | REVOLADE |
| Generic / active ingredient | ELTROMBOPAG (ELTROMBOPAG OLAMINE) : 50 MG |
| Manufacturer | NOVARTIS PHARMACEUTICALS CANADA INC |
| Strength | 50 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | B02BX05 ELTROMBOPAG |
| AHFS class | 20:16.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 16-Feb-2016 |
| Original market date | 2011-04-01 00:00:00 |
How is it administered?
Individualize dose based on platelet counts. ITP: Start 50mg daily (25mg for East-/Southeast-Asian). HCV: Start 25mg daily. SAA: Start 50mg daily (25mg for East-/Southeast-Asian or hepatic impairment).
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (section 11 referenced but content not shown).
How is it supplied?
Not explicitly detailed in provided text (mentions tablets and strengths).
Contraindications
Severe hepatic impairment (Child-Pugh Class C); hypersensitivity to eltrombopag or any ingredient in the formulation.
Warnings and precautions
Risk of hepatic decompensation and death in chronic hepatitis C patients with cirrhosis. Monitor for hepatotoxicity and thrombotic/thromboembolic complications.
What can be used instead?
Other Canadian products sharing ATC code B02BX05 ELTROMBOPAG. 4 of 8 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-ELTROMBOPAG | 25 MG | TABLET | APOTEX INC | MARKETED | DIN 02506742 |
| APO-ELTROMBOPAG | 50 MG | TABLET | APOTEX INC | MARKETED | DIN 02506769 |
| REVOLADE | 25 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02361825 |
| REVOLADE | 12.5 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | CANCELLED PRE MARKET | DIN 02461382 |
| REVOLADE | 75 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | CANCELLED PRE MARKET | DIN 02423049 |
| TEVA-ELTROMBOPAG | 25 MG | TABLET | TEVA CANADA LIMITED | APPROVED | DIN 02551721 |
| TEVA-ELTROMBOPAG | 50 MG | TABLET | TEVA CANADA LIMITED | APPROVED | DIN 02551748 |
Who else supplies ELTROMBOPAG worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ELTROMBOPAG appears in 217 registered pack listings across 13 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.